Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Vyvgart now approved in Canada for adults with AChR-related gMG

Health Canada has approved Vyvgart (efgartigimod alfa-fcab) to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common target of MG-causing antibodies. The approval is based on positive data from the Phase 3 ADAPT clinical trial (NCT03669588),…

Folia expands patient-reported platform to MG

Folia Health is expanding the use of its smartphone app for gathering self-reported patient health data to people with myasthenia gravis (MG) and other neurological conditions. Patients’ daily experiences will contribute to obtaining comprehensive data on disease progression and treatment response, which are expected to contribute to improving…

Pregnant women with MG at higher risk of complications: Review study

Pregnant women with myasthenia gravis (MG) are particularly susceptible to severe disease-related complications, usually caused by generalized muscle weakness, which can put the mother and child at risk, according to a recent review study. Newborns should also be monitored for symptoms of transient neonatal MG, a form of…

Ad Scientiam launches program to develop gMG digital biomarkers

Ad Scientiam has launched a program to develop and validate new digital biomarkers for self-assessing patients with generalized myasthenia gravis (gMG). The launch was announced on Rare Disease Day, Feb. 28, and is supported by Alexion, AstraZeneca Rare Disease. “Easy-to-use digital tools have the potential to generate reliable…

CD59 Protein Might Protect Against Immune System’s Action in MG

A protein called CD59 might protect the neuromuscular junction — the place where nerve cells come into contact and communicate with muscle cells — from the harmful action of the body’s immune system in myasthenia gravis (MG) patients, a study in Japan suggests. “CD59 overexpression might be required for…